Genmab (GMAB – Research Report) received a Buy rating and price target from William Blair analyst Matt Phipps today. The company’s shares ...

Genmab A/S (Nasdaq: GMAB) said on Monday that Johnson & Johnson (J&J) has decided not to exercise its option to obtain a ...

Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Genmab (GMAB – Research Report) today and set a price target of $31.00. The ...

Company Announcement Johnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 Genmab will not pursue ...

We recently compiled a list of the 15 Stocks That Will Go to The Moon According to Analysts. In this article, we are going to ...

In trading on Friday, shares of Genmab A/S (Symbol: GMAB) crossed above their 200 day moving average of $24.14, changing hands as high as $24.32 per share. Genmab A/S shares are currently trading ...

In this article, we are going to take a look at where Genmab A/S (NASDAQ:GMAB) stands against other best growth stocks to invest in according to analysts. Companies experiencing above-average ...

In this article, we are going to take a look at where Genmab A/S (NASDAQ:GMAB) stands against the other healthcare stocks. McKinsey reported that, since 2019, the US healthcare industry witnessed ...

Genmab (GMAB) and Sonic Automotive (SAH) are climbing 5% and 3%, respectively, after investment banks issued favorable notes about the stocks. Leerink Partners raised its rating on GMAB to ...

We recently compiled a list of the 10 Cash-Rich Undervalued Stocks To Invest In. In this article, we are going to take a look ...

1 Day GMAB 2.04% DJIA 0.37% S&P 500 -0.47% Health Care/Life Sciences -0.32% ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...